Travere Therapeutics falls on third quarter earnings miss
Travere Therapeutics (TVTX) reported a Q3 loss of -$0.55 per share, missing estimates, despite revenue of $224.56M beating forecasts. The miss was due to a $113.1M R&D expense. FILSPARI sales grew 120% YoY to $200.2M. R&D and SG&A expenses increased. Cash reserves were $471.8M as of Q3 2026.
How this was made
The 30-second read
Why it matters
The earnings miss triggered a 4.8% after‑hours decline, suggesting short‑term downside risk despite revenue growth.
Market read
First disclosure of Q3 financials for TVTX, providing actionable insight for traders.
What to watch
In‑process R&D expense is a one‑time charge; future quarters may improve if the Harmony study succeeds.
Background
Travere Therapeutics (NASDAQ:TVTX) announced its Q3 results, missing EPS expectations but beating revenue forecasts, with a notable $113.1 M in‑process R&D expense tied to a licensing deal.
Ticker impact
Travere Therapeutics reported Q3 loss of $0.55 per share, missing estimates and causing a 4.8% after‑hours share decline.
downward pressure as the market prices the earnings miss and higher expense outlook
The article provides the first disclosure of the quarter's loss, revenue, and expense details, which moved the stock 4.8% after‑hours.
Market effects
Biotech sector may see broader pressure as earnings miss highlights R&D cost risk.
U.S. biotech stocks could face short‑term weakness.
Limited to investors tracking biotech earnings.
Counterpoint
The revenue beat and strong FILSPARI sales could support a rebound if investors focus on top‑line growth.
Key entities
- companyTravere Therapeutics
Biopharma focused on rare kidney diseases.
- companyEverest Medicines
Partner in the licensing agreement for civorebrutinib.
